Business
Zelluna Receives Positive MHRA Feedback and Strengthens UK Clinical Strategy for ZI-MA4-1 Paving the Way for First-in-Human Trials in the UK
On track to file CTA by year end 2025, with plan to dose first patients and deliver initial data in 2026Planned UK trial to be led by Prof. Fiona Thistlethwaite at The Christie NHS Foundation Trust, a European hub for advanced therapies, with participation from Dr. Andrew Furness at The Royal Marsden, a world-renowned centre for oncology and early-phase clinical research Oslo, Norway, 9 October 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic (“off-the-shelf”) T Cell Receptor-based Na
About this update from Zelluna Asa
[{"type":"image","alt":"Zelluna ASA","displaySize":"","headline":null,"caption":"Zelluna ASA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":106,"url":"https://media.zenfs.com/en/globenewswire.com/a3f855525ffb13acd9e8579786771e69"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C3Qdgv86SfCXtr_6x5fSRg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a3f855525ffb13acd9e8579786771e69","width":300,"height":106}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"On track to file CTA by year end 2025, with plan to dose first patients and deliver initial data in 2026","length":104,"tagName":"p"}]},{"val":[{"type":"text","content":"Planned UK trial to be led by Prof. Fiona Thistlethwaite at The Christie NHS Foundation Trust, a European hub for advanced therapies, with participation from Dr. Andrew Furness at The Royal Marsden, a world-renowned centre for oncology and early-phase clinical research","length":269,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":373,"olType":false},{"type":"text","content":"Oslo, Norway, 9 October 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic (“off-the-shelf”) T Cell Receptor-based Natural Killer (TCR-NK) cells for the treatment of cancer, today announced it has received positive feedback from the United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) following recent scientific advice. This feedback provides alignment on the preclinical, manufacturing, clinical and regulatory pathway for ZI-MA4-1 and supports Zelluna’s planned Clinical Trial Application (CTA) submission later this year.","length":558,"tagName":"p"},{"type":"text","content":"In parallel, Zelluna has advanced preparations for the first-in-human trial of ZI-MA4-1 by engaging with leading UK cancer centres and appointing Professor Fiona Thistlethwaite, Medical Oncology Consultant at The Christie in Manchester, as proposed Chief Investigator. The Christie, one of Europe’s leading cancer centres and a major hub for advanced cell therapy research, will serve as a lead site for the study. Both Professor Fiona Thistlethwaite at The Christie and Dr. Andrew Furness at The Royal Marsden in London, a global leader in oncology and early-phase cell therapy studies, are expected to play central roles in the trial and have con...